Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-5876

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC ; volume:20 ; number:1 ; day:22 ; month:11 ; year:2022 ; pages:1-12 ; date:12.2022
Journal of translational medicine ; 20, Heft 1 (22.11.2022), 1-12, 12.2022

Creator: Della Corte, Carminia Maria
Ciaramella, Vincenza
Ramkumar, Kavya
Vicidomini, Giovanni
Fiorelli, Alfonso
Nardone, Valerio
Cappabianca, Salvatore
Cozzolino, Immacolata
Zito Marino, Federica
Di Guida, Gaetano
Wang, Qi
Cardnell, Robert
Gay, Carl Michael
Ciardiello, Davide
Martinelli, Erika
Troiani, Teresa
Martini, Giulia
Napolitano, Stefania
Wang, Jing
Byers, Lauren Averett
Ciardiello, Fortunato
Morgillo, Floriana

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12967-022-03730-y

URN: urn:nbn:de:101:1-2023020409003557615455

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Della Corte, Carminia Maria
Ciaramella, Vincenza
Ramkumar, Kavya
Vicidomini, Giovanni
Fiorelli, Alfonso
Nardone, Valerio
Cappabianca, Salvatore
Cozzolino, Immacolata
Zito Marino, Federica
Di Guida, Gaetano
Wang, Qi
Cardnell, Robert
Gay, Carl Michael
Ciardiello, Davide
Martinelli, Erika
Troiani, Teresa
Martini, Giulia
Napolitano, Stefania
Wang, Jing
Byers, Lauren Averett
Ciardiello, Fortunato
Morgillo, Floriana
SpringerLink (Online service)

Other Objects (12)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

Related objects

Reset password